Maze Therapeutics (NASDAQ:MAZE) Reaches New 52-Week High – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $31.93 and last traded at $29.52, with a volume of 280001 shares. The stock had previously closed at $29.75.

Analyst Ratings Changes

Several research analysts have commented on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Wedbush started coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 18th. BTIG Research raised their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.83.

Maze Therapeutics Trading Down 0.8%

The firm has a 50-day simple moving average of $21.32 and a 200-day simple moving average of $15.14.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Institutional Trading of Maze Therapeutics

Institutional investors have recently made changes to their positions in the business. New York State Common Retirement Fund acquired a new stake in shares of Maze Therapeutics in the 1st quarter worth $25,000. CWM LLC acquired a new stake in shares of Maze Therapeutics in the 2nd quarter worth $28,000. Corebridge Financial Inc. acquired a new stake in shares of Maze Therapeutics in the 1st quarter worth $48,000. Legal & General Group Plc boosted its position in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after purchasing an additional 3,774 shares in the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.